Promoting remyelination in multiple sclerosis: Current drugs and future prospects
Promoting remyelination in multiple sclerosis: Current drugs and future prospects
About this item
Full title
Author / Creator
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Myelin destruction due to inflammatory oligodendrocyte cell damage or death in conjunction with axonal degeneration are among the major histopathological hallmarks of multiple sclerosis (MS). The majority of available immunomodulatory medications for MS are approved for relapsing–remitting (RR) MS, for which they reduce relapse rate, MRI measures o...
Alternative Titles
Full title
Promoting remyelination in multiple sclerosis: Current drugs and future prospects
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1808716226
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1808716226
Other Identifiers
ISSN
1352-4585
E-ISSN
1477-0970
DOI
10.1177/1352458514566419
